Literature DB >> 30068596

Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Rashmi Gupta1, Xiao J Yan1, Jacqueline Barrientos2, Jonathan E Kolitz1,2,3, Steven L Allen1,2,3, Kanti Rai1,2,3, Nicholas Chiorazzi1,3,4, Patricia K A Mongini5.   

Abstract

Malignant cell growth within patients with B cell chronic lymphocytic leukemia (B-CLL) is largely restricted to lymphoid tissues, particularly lymph nodes. The recent in vitro finding that TLR-9 ligand (oligodeoxynucleotide [ODN]) and IL-15 exhibit strong synergy in promoting B-CLL growth may be particularly relevant to growth in these sites. This study shows IL-15-producing cells are prevalent within B-CLL-infiltrated lymph nodes and, using purified B-CLL cells from blood, investigates the mechanism for ODN and IL-15 synergy in driving B-CLL growth. ODN boosts baseline levels of phospho-RelA(S529) in B-CLL and promotes NF-κB-driven increases in IL15RA and IL2RB mRNA, followed by elevated IL-15Rα and IL-2/IL-15Rβ (CD122) protein. IL-15CD122 signaling during a critical interval, 20 to 36-48 h following initial ODN exposure, is required for optimal induction of the cycling process. Furthermore, experiments with neutralizing anti-IL-15 and anti-CD122 mAbs indicate that clonal expansion requires continued IL-15/CD122 signaling during cycling. The latter is consistent with evidence of heightened IL2RB mRNA in the fraction of recently proliferated B-CLL cells within patient peripheral blood. Compromised ODN+IL-15 growth with limited cell density is consistent with a role for upregulated IL-15Rα in facilitating homotypic trans IL-15 signaling, although there may be other explanations. Together, the findings show that ODN and IL-15 elicit temporally distinct signals that function in a coordinated manner to drive B-CLL clonal expansion.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30068596      PMCID: PMC6103916          DOI: 10.4049/jimmunol.1800591

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  95 in total

Review 1.  Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.

Authors:  F Piazza; S Manni; M Ruzzene; L A Pinna; C Gurrieri; G Semenzato
Journal:  Leukemia       Date:  2012-01-13       Impact factor: 11.528

2.  Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.

Authors:  Bernd Jahrsdörfer; James E Wooldridge; Sue E Blackwell; Christiana M Taylor; Thomas S Griffith; Brian K Link; George J Weiner
Journal:  J Leukoc Biol       Date:  2004-12-06       Impact factor: 4.962

3.  Proliferation centers in chronic lymphocytic leukemia: the niche where NF-kappaB activation takes place.

Authors:  B Herreros; S M Rodríguez-Pinilla; R Pajares; M A Martínez-Gónzalez; R Ramos; I Munoz; S Montes-Moreno; M Lozano; L Sánchez-Verde; G Roncador; M Sánchez-Beato; R D de Otazu; M Pérez-Guillermo; M J Mestre; C Bellas; M A Piris
Journal:  Leukemia       Date:  2010-01-14       Impact factor: 11.528

4.  Activation of nuclear transcription factor NF-kappaB by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit.

Authors:  T A Bird; K Schooley; S K Dower; H Hagen; G D Virca
Journal:  J Biol Chem       Date:  1997-12-19       Impact factor: 5.157

5.  Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.

Authors:  T Decker; F Schneller; M Kronschnabl; T Dechow; G B Lipford; H Wagner; C Peschel
Journal:  Exp Hematol       Date:  2000-05       Impact factor: 3.084

6.  Characterization of interleukin 2 receptors on B-cell chronic lymphocytic leukemia cells.

Authors:  V Tsilivakos; A Tsapis; S Kakolyris; P Iliakis; M Perraki; V Georgoulias
Journal:  Leukemia       Date:  1994-09       Impact factor: 11.528

7.  Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes.

Authors:  Seiji Yokoyama; Nobumasa Watanabe; Noriko Sato; Pin-Yu Perera; Lyvouch Filkoski; Toshiyuki Tanaka; Masayuki Miyasaka; Thomas A Waldmann; Takachika Hiroi; Liyanage P Perera
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-01       Impact factor: 11.205

8.  Elevated and sustained expression of the transcription factors Egr1 and Egr2 controls NKT lineage differentiation in response to TCR signaling.

Authors:  Michael P Seiler; Rebecca Mathew; Megan K Liszewski; Chauncey J Spooner; Chauncey Spooner; Kenneth Barr; Fanyong Meng; Harinder Singh; Albert Bendelac
Journal:  Nat Immunol       Date:  2012-02-05       Impact factor: 25.606

9.  Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.

Authors:  Thomas M Herndon; Shih-Shih Chen; Nakhle S Saba; Janet Valdez; Claire Emson; Michelle Gatmaitan; Xin Tian; Thomas E Hughes; Clare Sun; Diane C Arthur; Maryalice Stetler-Stevenson; Constance M Yuan; Carsten U Niemann; Gerald E Marti; Georg Aue; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Nicholas Chiorazzi; Adrian Wiestner
Journal:  Leukemia       Date:  2017-01-11       Impact factor: 11.528

10.  A rapid method for quantifying cytoplasmic versus nuclear localization in endogenous peripheral blood leukocytes by conventional flow cytometry.

Authors:  George C Brittain; Sergei Gulnik
Journal:  Cytometry A       Date:  2017-03-30       Impact factor: 4.355

View more
  4 in total

1.  Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status.

Authors:  Federico Carlini; Federico Ivaldi; Francesca Gualandi; Ursula Boschert; Diego Centonze; Giuseppe Matarese; Marco Salvetti; Nicole Kerlero de Rosbo; Antonio Uccelli
Journal:  J Neuroimmune Pharmacol       Date:  2021-04-14       Impact factor: 4.147

2.  Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.

Authors:  Rashmi Gupta; Wentian Li; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2019-04-15       Impact factor: 5.422

3.  Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.

Authors:  Kallesh D Jayappa; Vicki L Gordon; Christopher G Morris; Briana Wilson; B Dharmaveer Shetty; Konrad J Cios; Puja C Arora; Krista M Isaac; Shekhar Saha; Timothy P Bender; Michael E Williams; Craig A Portell; Michael J Weber
Journal:  Blood Adv       Date:  2021-09-14

4.  Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication.

Authors:  Pin Lu; Shengchun Wang; Carrie A Franzen; Girish Venkataraman; Rebecca McClure; Lei Li; Wenjun Wu; Nifang Niu; Madina Sukhanova; Jianming Pei; Donald A Baldwin; Reza Nejati; Mariusz A Wasik; Nadia Khan; Yifan Tu; Juehua Gao; Yihua Chen; Shuo Ma; Richard A Larson; Y Lynn Wang
Journal:  Blood Cancer J       Date:  2021-02-18       Impact factor: 9.812

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.